Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shawn Peffall

Internal Medicine Baltimore, MD Medical Doctor

NPI 1457318933 CMS profile 20822

7602 Belair Rd, Baltimore, MD 21236

Open in the dashboard

General payments

$1,273

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shawn Peffall of Baltimore, MD is reported in the CMS Open Payments database as having received $1,273 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $247 12
2024 General $244 13
2023 General $151 9
2020 General $51 3
2019 General $581 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shawn Peffall
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Shawn Peffall were reported at $247. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Shawn Peffall Internal Medicine median Middle half National median
2019 $581 $159 $48–$570 $163
2020 $51 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $151 $149 $45–$519 $160
2024 $244 $154 $47–$537 $164
2025 $247 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $185 9 payments
  2. Amgen Inc. $144 9 payments
  3. Novo Nordisk Inc $130 7 payments
  4. Exact Sciences Corporation $77 3 payments
  5. GlaxoSmithKline, LLC. $68 5 payments
  6. Salix Pharmaceuticals, a division of Bausch Health US, LLC $64 4 payments
  7. Janssen Pharmaceuticals, Inc $60 4 payments
  8. Lilly USA, LLC $56 5 payments
  9. Allergan Inc. $55 3 payments
  10. Sanofi-Aventis U.S. LLC $54 4 payments
  11. Other $380 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,273 77 payments
Products named General payments · program years 2019–2025
  1. Otezla $127 8 payments
  2. Repatha $113 7 payments
  3. Ozempic $107 6 payments
  4. CREON $86 3 payments
  5. RYBELSUS $72 4 payments
  6. UBRELVY $69 4 payments
  7. LINZESS $65 3 payments
  8. XIFAXAN $64 4 payments
  9. XARELTO $60 4 payments
  10. FARXIGA $52 4 payments
  11. Other $1,123 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 162 drugs

Part D claims

10,544

Median for Dermatology: 534

Drug cost

$771,754

Median for Dermatology: $67,151

Branded share of claims

20.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 116 $130,057
Eliquis Apixaban Brand 103 $122,867
Jardiance Empagliflozin Brand 93 $111,434
Trulicity Dulaglutide Brand 47 $62,848
Xarelto Rivaroxaban Brand 48 $59,832
Mounjaro Tirzepatide Brand 31 $32,538
Rybelsus Semaglutide Brand 21 $31,129
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 27 $19,286
Atrovent Hfa Ipratropium Bromide Brand 16 $12,721
Breo Ellipta Fluticasone/Vilanterol Brand 17 $10,487

The 10 drugs with the highest cost, of 162 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$151,324

Of which drugs: $26,055

Medicare patients

504

Average age 73

Services billed

1,865

249 women, 255 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 60%
Ischemic heart disease 43%
Diabetes 27%
Depression 23%
COPD 21%
Cancer 19%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 55 55 $15,945
Vaccine for influenza for injection into muscle 90653 Office 96 96 $7,855

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CREON
  • AbbVie, Inc. $44
$44 — —
Otezla
  • Amgen Inc. $30
$30 — —
Repatha
  • Amgen Inc. $30
$30 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $18
$18 — —
Veozah
  • Astellas Pharma US Inc $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record